Drug repurposing is time- and cost-saving compared with de novo drug development
In the 24-week, placebo-controlled factorial study of initial therapy with JANUVIA in combination with metformin, the incidence of hypoglycemia was 0.6% in patients given placebo, 0.6% in patients given JANUVIA alone, 0.8% in patients given metformin alone, and 1.6% in patients given JANUVIA in combination with metformin
Gradual dose escalation is recommended to minimize side effects
Participants achieved clinically meaningful reductions in body weight versus placebo over 42 weeks, and both companies featured the data in a dedicated symposium on amylin as a novel diabetes and obesity therapy
MSC-derived extracellular vesicles as nanotherapeutics for promoting aged liver regeneration
In case the patient does not tolerate the maximum dose (2.4 mg), the dose may be down-titrated to 1.7 mg to offer a balance between efficient weight loss and tolerable side effects